Estimating demand for anti-Chagas drugs: a contribution for access in Latin America
Describe a tool to estimate demand for benznidazole and nifurtimox to treat Chagas disease, and report on its implementation in a group of Latin American countries. The project was carried out in the following stages: 1) development of a tool to estimate demand, and definition of the evaluation and...
Gespeichert in:
Veröffentlicht in: | Revista panamericana de salud pública 2017-06, Vol.41, p.e45 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | spa |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | e45 |
container_title | Revista panamericana de salud pública |
container_volume | 41 |
creator | Chaves, Gabriela Costa Abi-Saab Arrieche, Mariana Rode, Joelle Mechali, Daniel Reis, Priscileyne Ouverney Alves, Renato Vieira Stobbaerts, Eric Aguilar, Nora Girón Ribeiro, Isabela |
description | Describe a tool to estimate demand for benznidazole and nifurtimox to treat Chagas disease, and report on its implementation in a group of Latin American countries.
The project was carried out in the following stages: 1) development of a tool to estimate demand, and definition of the evaluation and decision variables to estimate demand 2) data collection via a questionnaire completed by representatives of control programs, complemented with data from the literature; 3) presentation of the tool, followed by validation, and adaptation by representatives of the control programs in order to plan drug procurement for 2012 and 2013; and 4) further analysis of the obtained data, especially regarding benznidazole, and comparison of country estimates.
Fourteen endemic countries of Latin America took part in the third stage, and a consolidated estimate was made. The number of estimated treatments, based on the number of tablets per treatment established in the regimen of reference was: 867 in the group under 1 year of age; 2 042 835 in the group from 1 to 15 years old; 2 028 in the group from 15 to 20 years old; and 10 248 in adults over 20. This means that it is possible to provide benznidazole to less than 1% of people for whom treatment is indicated.
The development and systematic use of demand management tools can play a key role in helping to provide access to the anti-Chagas drugs. There is a significant gap between the projected demand for drugs and current estimates of prevalence rates. |
format | Article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_28614468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28614468</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-6d2a7d757a2ad89ec4352564b538ffce65b1eb7715a9e3bdb704302a45eff31c3</originalsourceid><addsrcrecordid>eNo1j8tKAzEUQIMgba39BckPDEzeqbsy1AcMdKGuy81rjDiZIcks_HuV6upsDgfOFdoQqdtGMK7X6KaUj7alRDKyQmuqJeFc6g16OZYaR6gxDdj5EZLDYcoYUo1N9w4DFOzyMpR7DNhOqeZolhqndLGs9aXgmHD_W8CH0edo4RZdB_gsfvfHLXp7OL52T01_enzuDn0zE05qIx0F5ZRQQMHpvbecCSokN4LpEKyXwhBvlCIC9p4ZZ1TLWUuBCx8CI5Zt0d2lOy9m9O4855-T_HX-v2PfZ_1K-w</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Estimating demand for anti-Chagas drugs: a contribution for access in Latin America</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Chaves, Gabriela Costa ; Abi-Saab Arrieche, Mariana ; Rode, Joelle ; Mechali, Daniel ; Reis, Priscileyne Ouverney ; Alves, Renato Vieira ; Stobbaerts, Eric ; Aguilar, Nora Girón ; Ribeiro, Isabela</creator><creatorcontrib>Chaves, Gabriela Costa ; Abi-Saab Arrieche, Mariana ; Rode, Joelle ; Mechali, Daniel ; Reis, Priscileyne Ouverney ; Alves, Renato Vieira ; Stobbaerts, Eric ; Aguilar, Nora Girón ; Ribeiro, Isabela</creatorcontrib><description>Describe a tool to estimate demand for benznidazole and nifurtimox to treat Chagas disease, and report on its implementation in a group of Latin American countries.
The project was carried out in the following stages: 1) development of a tool to estimate demand, and definition of the evaluation and decision variables to estimate demand 2) data collection via a questionnaire completed by representatives of control programs, complemented with data from the literature; 3) presentation of the tool, followed by validation, and adaptation by representatives of the control programs in order to plan drug procurement for 2012 and 2013; and 4) further analysis of the obtained data, especially regarding benznidazole, and comparison of country estimates.
Fourteen endemic countries of Latin America took part in the third stage, and a consolidated estimate was made. The number of estimated treatments, based on the number of tablets per treatment established in the regimen of reference was: 867 in the group under 1 year of age; 2 042 835 in the group from 1 to 15 years old; 2 028 in the group from 15 to 20 years old; and 10 248 in adults over 20. This means that it is possible to provide benznidazole to less than 1% of people for whom treatment is indicated.
The development and systematic use of demand management tools can play a key role in helping to provide access to the anti-Chagas drugs. There is a significant gap between the projected demand for drugs and current estimates of prevalence rates.</description><identifier>EISSN: 1680-5348</identifier><identifier>PMID: 28614468</identifier><language>spa</language><publisher>United States</publisher><subject>Adolescent ; Adult ; Chagas Disease - drug therapy ; Child ; Child, Preschool ; Humans ; Infant ; Latin America ; Nifurtimox - supply & distribution ; Nifurtimox - therapeutic use ; Nitroimidazoles - supply & distribution ; Nitroimidazoles - therapeutic use ; Trypanocidal Agents - supply & distribution ; Trypanocidal Agents - therapeutic use ; Young Adult</subject><ispartof>Revista panamericana de salud pública, 2017-06, Vol.41, p.e45</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28614468$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chaves, Gabriela Costa</creatorcontrib><creatorcontrib>Abi-Saab Arrieche, Mariana</creatorcontrib><creatorcontrib>Rode, Joelle</creatorcontrib><creatorcontrib>Mechali, Daniel</creatorcontrib><creatorcontrib>Reis, Priscileyne Ouverney</creatorcontrib><creatorcontrib>Alves, Renato Vieira</creatorcontrib><creatorcontrib>Stobbaerts, Eric</creatorcontrib><creatorcontrib>Aguilar, Nora Girón</creatorcontrib><creatorcontrib>Ribeiro, Isabela</creatorcontrib><title>Estimating demand for anti-Chagas drugs: a contribution for access in Latin America</title><title>Revista panamericana de salud pública</title><addtitle>Rev Panam Salud Publica</addtitle><description>Describe a tool to estimate demand for benznidazole and nifurtimox to treat Chagas disease, and report on its implementation in a group of Latin American countries.
The project was carried out in the following stages: 1) development of a tool to estimate demand, and definition of the evaluation and decision variables to estimate demand 2) data collection via a questionnaire completed by representatives of control programs, complemented with data from the literature; 3) presentation of the tool, followed by validation, and adaptation by representatives of the control programs in order to plan drug procurement for 2012 and 2013; and 4) further analysis of the obtained data, especially regarding benznidazole, and comparison of country estimates.
Fourteen endemic countries of Latin America took part in the third stage, and a consolidated estimate was made. The number of estimated treatments, based on the number of tablets per treatment established in the regimen of reference was: 867 in the group under 1 year of age; 2 042 835 in the group from 1 to 15 years old; 2 028 in the group from 15 to 20 years old; and 10 248 in adults over 20. This means that it is possible to provide benznidazole to less than 1% of people for whom treatment is indicated.
The development and systematic use of demand management tools can play a key role in helping to provide access to the anti-Chagas drugs. There is a significant gap between the projected demand for drugs and current estimates of prevalence rates.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Chagas Disease - drug therapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Humans</subject><subject>Infant</subject><subject>Latin America</subject><subject>Nifurtimox - supply & distribution</subject><subject>Nifurtimox - therapeutic use</subject><subject>Nitroimidazoles - supply & distribution</subject><subject>Nitroimidazoles - therapeutic use</subject><subject>Trypanocidal Agents - supply & distribution</subject><subject>Trypanocidal Agents - therapeutic use</subject><subject>Young Adult</subject><issn>1680-5348</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j8tKAzEUQIMgba39BckPDEzeqbsy1AcMdKGuy81rjDiZIcks_HuV6upsDgfOFdoQqdtGMK7X6KaUj7alRDKyQmuqJeFc6g16OZYaR6gxDdj5EZLDYcoYUo1N9w4DFOzyMpR7DNhOqeZolhqndLGs9aXgmHD_W8CH0edo4RZdB_gsfvfHLXp7OL52T01_enzuDn0zE05qIx0F5ZRQQMHpvbecCSokN4LpEKyXwhBvlCIC9p4ZZ1TLWUuBCx8CI5Zt0d2lOy9m9O4855-T_HX-v2PfZ_1K-w</recordid><startdate>20170608</startdate><enddate>20170608</enddate><creator>Chaves, Gabriela Costa</creator><creator>Abi-Saab Arrieche, Mariana</creator><creator>Rode, Joelle</creator><creator>Mechali, Daniel</creator><creator>Reis, Priscileyne Ouverney</creator><creator>Alves, Renato Vieira</creator><creator>Stobbaerts, Eric</creator><creator>Aguilar, Nora Girón</creator><creator>Ribeiro, Isabela</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20170608</creationdate><title>Estimating demand for anti-Chagas drugs: a contribution for access in Latin America</title><author>Chaves, Gabriela Costa ; Abi-Saab Arrieche, Mariana ; Rode, Joelle ; Mechali, Daniel ; Reis, Priscileyne Ouverney ; Alves, Renato Vieira ; Stobbaerts, Eric ; Aguilar, Nora Girón ; Ribeiro, Isabela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-6d2a7d757a2ad89ec4352564b538ffce65b1eb7715a9e3bdb704302a45eff31c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Chagas Disease - drug therapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Humans</topic><topic>Infant</topic><topic>Latin America</topic><topic>Nifurtimox - supply & distribution</topic><topic>Nifurtimox - therapeutic use</topic><topic>Nitroimidazoles - supply & distribution</topic><topic>Nitroimidazoles - therapeutic use</topic><topic>Trypanocidal Agents - supply & distribution</topic><topic>Trypanocidal Agents - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chaves, Gabriela Costa</creatorcontrib><creatorcontrib>Abi-Saab Arrieche, Mariana</creatorcontrib><creatorcontrib>Rode, Joelle</creatorcontrib><creatorcontrib>Mechali, Daniel</creatorcontrib><creatorcontrib>Reis, Priscileyne Ouverney</creatorcontrib><creatorcontrib>Alves, Renato Vieira</creatorcontrib><creatorcontrib>Stobbaerts, Eric</creatorcontrib><creatorcontrib>Aguilar, Nora Girón</creatorcontrib><creatorcontrib>Ribeiro, Isabela</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Revista panamericana de salud pública</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chaves, Gabriela Costa</au><au>Abi-Saab Arrieche, Mariana</au><au>Rode, Joelle</au><au>Mechali, Daniel</au><au>Reis, Priscileyne Ouverney</au><au>Alves, Renato Vieira</au><au>Stobbaerts, Eric</au><au>Aguilar, Nora Girón</au><au>Ribeiro, Isabela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estimating demand for anti-Chagas drugs: a contribution for access in Latin America</atitle><jtitle>Revista panamericana de salud pública</jtitle><addtitle>Rev Panam Salud Publica</addtitle><date>2017-06-08</date><risdate>2017</risdate><volume>41</volume><spage>e45</spage><pages>e45-</pages><eissn>1680-5348</eissn><abstract>Describe a tool to estimate demand for benznidazole and nifurtimox to treat Chagas disease, and report on its implementation in a group of Latin American countries.
The project was carried out in the following stages: 1) development of a tool to estimate demand, and definition of the evaluation and decision variables to estimate demand 2) data collection via a questionnaire completed by representatives of control programs, complemented with data from the literature; 3) presentation of the tool, followed by validation, and adaptation by representatives of the control programs in order to plan drug procurement for 2012 and 2013; and 4) further analysis of the obtained data, especially regarding benznidazole, and comparison of country estimates.
Fourteen endemic countries of Latin America took part in the third stage, and a consolidated estimate was made. The number of estimated treatments, based on the number of tablets per treatment established in the regimen of reference was: 867 in the group under 1 year of age; 2 042 835 in the group from 1 to 15 years old; 2 028 in the group from 15 to 20 years old; and 10 248 in adults over 20. This means that it is possible to provide benznidazole to less than 1% of people for whom treatment is indicated.
The development and systematic use of demand management tools can play a key role in helping to provide access to the anti-Chagas drugs. There is a significant gap between the projected demand for drugs and current estimates of prevalence rates.</abstract><cop>United States</cop><pmid>28614468</pmid></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1680-5348 |
ispartof | Revista panamericana de salud pública, 2017-06, Vol.41, p.e45 |
issn | 1680-5348 |
language | spa |
recordid | cdi_pubmed_primary_28614468 |
source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Adolescent Adult Chagas Disease - drug therapy Child Child, Preschool Humans Infant Latin America Nifurtimox - supply & distribution Nifurtimox - therapeutic use Nitroimidazoles - supply & distribution Nitroimidazoles - therapeutic use Trypanocidal Agents - supply & distribution Trypanocidal Agents - therapeutic use Young Adult |
title | Estimating demand for anti-Chagas drugs: a contribution for access in Latin America |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T08%3A35%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estimating%20demand%20for%20anti-Chagas%20drugs:%20a%20contribution%20for%20access%20in%20Latin%20America&rft.jtitle=Revista%20panamericana%20de%20salud%20p%C3%BAblica&rft.au=Chaves,%20Gabriela%20Costa&rft.date=2017-06-08&rft.volume=41&rft.spage=e45&rft.pages=e45-&rft.eissn=1680-5348&rft_id=info:doi/&rft_dat=%3Cpubmed%3E28614468%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28614468&rfr_iscdi=true |